Inventurus Knowledge Solutions (IKS) Q1 25/26 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 25/26 earnings summary
6 Jan, 2026Executive summary
Achieved 16% year-on-year revenue growth in Q1 FY26, reaching INR 7,401 million, with EBITDA up 36% to INR 2,378 million and PAT up 59% to INR 1,515 million.
Maintained strong client relationships, with 95%+ revenues from repeat customers and over 450 enterprise clients.
Workforce globally diversified with 12,368 employees, including 2,260 clinically trained staff and 45% women.
Strong execution across five strategic vectors, including AI-native platform, AQuity integration, and outcome-oriented deals.
Standalone and consolidated unaudited financial results for Q1 FY26 were reviewed and approved by the Board and auditors, with no material misstatements identified.
Financial highlights
Q1 FY26 revenue was INR 7,401 million, up 15.6% YoY; USD revenue was $87 million, up 13.2% YoY.
EBITDA margin improved to 32–33.3%, with adjusted EBITDA per employee annualized at INR 0.81 million.
PAT margin at 20.5%, with basic EPS at INR 8.9, up 57.7% YoY.
Operating cash flow for the quarter was INR 1,658 million; free cash flow at INR 1,374 million after a $5M performance guarantee.
Net debt reduced to INR 4,486 million as of June 30, 2025, reflecting ongoing debt repayment.
Outlook and guidance
Expect continued headwinds from AQuity tail reduction and margin optimization for 2–3 more quarters.
Focus on margin expansion, technology-led solutions, and outcome-oriented deals to drive future growth.
Anticipate return to organic growth rates above the 12% outsourced TAM rate post tail-cutting.
Margin guidance remains early to mid 30s for EBITDA, with stabilization expected after AQuity transition completes.
Strategic investments and partnerships expected to enhance platform stickiness and support capital-light growth.
Latest events from Inventurus Knowledge Solutions
- Q3 FY26 saw 24% revenue growth, 40%+ EBITDA growth, and strong cash generation.IKS
Q3 25/265 Feb 2026 - Q2 FY26 delivered strong growth, margin expansion, and strategic investment in healthcare tech.IKS
Q2 25/263 Feb 2026 - 16% revenue growth, 31% EBITDA margin, and major client wins marked Q3 FY25.IKS
Q3 24/259 Jan 2026 - Strong revenue and margin growth, major platform wins, and high cash generation in FY25.IKS
Q4 24/256 Jan 2026